Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of analysts have commented on COLL shares. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Finally, Needham & Company LLC cut their target price on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday.

Insider Buying and Selling

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president directly owned 103,613 shares in the company, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of large investors have recently made changes to their positions in COLL. Janus Henderson Group PLC increased its position in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Collegium Pharmaceutical by 161.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after buying an additional 242,310 shares during the last quarter.

Collegium Pharmaceutical Trading Down 1.3%

Shares of Collegium Pharmaceutical stock opened at $41.11 on Monday. The company has a 50-day moving average of $46.50 and a two-hundred day moving average of $42.09. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $50.79. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The stock has a market cap of $1.31 billion, a PE ratio of 24.07 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. During the same period last year, the firm earned $1.77 EPS. Collegium Pharmaceutical’s revenue was up 12.9% compared to the same quarter last year. On average, research analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.